The Glucagon-like peptide-1 (GLP-1) enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of GLP-1 in EDTA plasma and other biological fluids.
| Catalog Number | |
|---|---|
| Packaging | 96 well microtiter |
| Detection | HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter |
| Dynamic Range | 6, 15-213 pg/mL |
| Species Reactivity | Enquire about animal-specific cross-reactivity |
| Limit of Detection | 1.9 pg/mL |
| Sample Size | 50 µL |
| Sample Type | Plasma |
| Assay Time | 2.5 hours |
| Shelf Life | 24 months |
| Availability | Worldwide |
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid gut hormone secreted from the intestinal L-cells. The GLP-1 sequence is highly conserved among mammals and is released in its active form (7-36) in response to food intake. It is quickly degraded into its inactive form (9-36) after selective cleavage by dipeptidyl peptidase-4 (DPP-4). GLP-1 reduces glucose levels by regulating pancreatic secretion, slowing gastric emptying and lowering the desire for food intake. Therefore, it is an important biomarker for the study of diabetes and obesity.1-5 This kit is designed to measures total of GLP-1.
References:
- Gareth E. Lim and Patricia L. Brubaker., Glucagon-Like Peptide 1 Secretion by the L-Cell. Diabetes 2006 Dec; 55(Supplement 2): S70-S77.
- Holst, Jens J. et al., Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends in Molecular Medicine 2008; 14(4): 161 – 168.
- Bak MJ, et.al., Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab. 2014 Nov;16(11):1155-64.
- Caporarello N,et.al., Insulin receptor signaling and glucagon-like peptide 1 effects on pancreatic beta cells. PLoS One. 2017 Aug 2;12(8): 1-11.
- Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014 Jan;63(1):9-19.Sandoval DA and D’Alessio DA. Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease. Physiol Rev 95:513-548.
GLP-1 ELISA AL-172
Kim S, Abbasi F, Nachmanoff C, Kumar A, Kalra B, Savjani G, Mantzoros C. Effect of Liraglutide Treatment on Proglucagon-Derived Peptides. JESOCI, Volume 4, Abstract Supplement, 2020
All Products Cited: GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Glucagon ELISA AL-127; Oxyntomodulin ELISA AL-139; Glicentin ELISA AL-185; MPGF ELISA AL-175
Shah A, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Gnatuk CL, Estes SJ, Allison KC, Sarwer DB, Sluss PM, Coutifaris C, Dokras A, Legro RS. Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS. J Clin Endocrinol Metab. 2021 Jan 1;106(1):108-119. doi:10.1210/clinem/dgaa682. PMID: 32968804; PMCID: PMC7765645
All Products Cited: Activin A ELISA AL-110; Activin AB ELISA AL-153; Inhibin A ELISA AL-123; Inhibin B ELISA AL-107; AMH ELISA AL-105, IGF-I ELISA AL-121, IGFBP-2 ELISA AL-140; GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Follistatin ELISA AL-117; Oxyntomodulin ELISA AL-139; Glucagon ELISA AL-157
Kim SH, Abbasi F, Nachmanoff C, Stefanakis K, Kumar A, Kalra B, Savjani G, Mantzoros CS. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial. Diabetes Obes Metab. 2021 Feb;23(2):489-498. doi: 10.1111/dom.14242
All Products Cited: GLP-1 ELISA AL-172
Kumar A, Kalra B, Mistry S, Patel AS, Budhavarapu V, Chatterji T, Savjani G, Krishna R, D’Alessio D. Development of Novel Specific and Sensitive ELISAs for Proglucagon-Derived Peptides. Poster presented at 69th AACC Meeting; 2017 July 30-Aug 3; San Diego, CA
All Products Cited: Glucagon ELISA AL-157; GLP-1 ELISA AL-172; Oxyntomodulin ELISA AL-139
D’Alessio D, Kumar A, Kalra B, Mistry S, Tong J. Novel ELISA Assays Demonstrate Specificity of Islet and Intestinal Processing of Proglucagon. Volume 4, Issue Supplement_1, April_May 2020, SUN-LB124, https://doi.org/10
All Products Cited: GLP-1 ELISA AL-172; Glucagon ELISA AL-157; Oxyntomodulin ELISA AL-139; Glicentin ELISA AL-185
Polyzos SA, Perakakis N, Boutari C, Kountouras J, Ghaly W, Anastasilakis AD, Karagiannis A, Mantzoros CS. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e390–400. doi: 10.1210/clinem/dgz172. PMID: 31690932;
PMCID: PMC7112980.
All Products Cited: GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Glucagon ELISA AL-157; MPGF ELISA AL-175; Oxyntomodulin ELISA AL-139; Follistatin-Like 3 ELISA AL-152; Activin B ELISA AL-150; IGF-I ELISA AL-121; Total IGFBP-3 ELISA AL-120; Intact IGFBP-3 ELISA AL-149; Total IGFBP-4 ELISA AL-126; Intact IGFBP-4 ELISA AL-128; picoPAPP-A ELISA AL-101
Perakakis N, Kalra B, Angelidi AM, Kumar A, Gavrieli A, MYannakoulia M, Mantzoros CS. Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial. Metabolism, Volume 129, 2022, 155157, ISSN 0026-0495,
https://doi.org/10.1016/j.metabol.2022.155157.
All Products Cited: GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Oxyntomodulin ELISA AL-139; Glicentin ELISA AL-185; Glucagon ELISA AL-127; MPGF ELISA AL-175; C-Peptide of Insulin ELISA AL-151